---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-266717"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2026-06-11T12:00:15+00:00"
generated_at: "2026-06-11T12:05:36.664560+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Atossa raises $4.5M in registered direct offering of stock and warrants

## Summary
- Sold 1,363,638 shares at $3.30/share plus Series A and B warrants for 1,363,638 shares each at $4.40.
- Net proceeds ~$4.1M; expected close June 12, 2026; funds for clinical development and working capital.
- Placement agent gets 7% cash fee plus warrants for 123,000 shares at $4.125.
- Series A warrants expire in 5.5 years, Series B in 2 years; exercise begins 6 months after issuance.
- Potential additional gross proceeds of ~$12M if fully exercised, but no assurance.

## SEC filing metadata
- accession: 0001193125-26-266717
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2026-06-11T12:00:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/0001193125-26-266717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/atos-20260610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-266717
- JSON: https://secwatch.observer/filing/0001193125-26-266717.json
- Plain text: https://secwatch.observer/filing/0001193125-26-266717.txt

## Key facts
- Material Agreements
  ATOSSA THERAPEUTICS, INC. entered into Purchase Agreement with institutional investors valued at approximately $4.1 million (effective 2026-06-10).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: institutional investors
  - Value: approximately $4.1 million
  - Effective: 2026-06-10
  source text: On June 10, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/0001193125-26-266717-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.